Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRPant-M alone or with radiotherapy in relapsed/refractory NHL
NCT05967416Phase 1Recruiting
- Sponsor
- SIRPant Immunotherapeutics
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- CAR-Macrophages
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIRPant-M in non-Hodgkin lymphoma (NHL) (6 arms), sponsored by SIRPant Immunotherapeutics. Primary endpoint: Incidence of treatment emergent adverse events (TEAEs) and adverse events (AEs). Started Jan 2024; status: recruiting.
02
Drugs
SIRPant-M
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05967416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967416.